Michael Burkes, CEO of Nater, Inc. (Nasdaq :), recently made several transactions that include ordinary company shares. According to a recent application to SEC, Burkes sold shares in a total value of $ 247,378. These sales were made over several days and prices ranged from $ 171.09 to $ 172.44 per share. Transactions followed after Nater’s shares showed outstanding results, with Investingpro data showing a return of 159% over the past year.
Burkes sold 495 shares at the price of $ 171.09 on January 2nd. Each. The next day, January 24, he sold an additional 687 shares of $ 171.80 per share and 259 shares of $ 172.44 per share. These transactions were made according to the 10B5-1 rules trading plan, which allows insiders to set a predetermined schedule for the sale of shares to avoid potential charges of trading privileged information.
Prior to this sale, Burkes acquired 1,250 shares of ordinary shares on January 2,250 through the acquisition of limited shareholding units (RSU). These RSUs have been transformed into ordinary shares as part of its compensation package without the direct purchase price included.
After these transactions, Burkes holds a total of 109,474 shares.
In other recent news, Nadera Inc . experienced significant progress. Barclays (Lon 🙂 raised Nater’s shares rating on Overweight with a goal of $ 200, stating the successful expansion of the company in new markets. TD Cowen also repeated the rating of buy for Nater shares, raising the target price with $ 175 at $ 195. Both companies highlight the impressive growth of the company’s revenue, with a recent record revenue in the third quarter of $ 439.8 million, which is an increase of 64% compared to the previous year.
Natera also expanded its dispute against neogenomics (Nasdaq 🙂 Due to a violation of patent that includes radar test, while facing failure in a lawsuit against false advertising Health guard (Nasdaq :). The company plans to request a judgment from the court in the latter case. Furthermore, an agreement with the executive president, Dr. Rabinowitz, was amended to continue his role under certain conditions.
These recent developments give an insight into Nterine’s current status and future prospects. However, it is important to note that they are based on the expectations of analysts and their own reports of the company, and investors should conduct their own research and deep analysis.
This article was generated with the support of AI and was examined by the editor. See our T&C for more information.
